Literature DB >> 20015604

Proteomic identification of human serum biomarkers in diabetes mellitus type 2.

Samreen Riaz1, Saadia Shahzad Alam, M Waheed Akhtar.   

Abstract

Discovery of protein biomarkers in different diseases is an important area of research in the field of proteomics. We have described the levels of protein biomarkers specific to diabetes mellitus type 2 in the local population of Pakistan using proteomic technology. Type 2 diabetic patients, age and sex-matched normal healthy controls were recruited from Sheikh Zayed Hospital, Lahore, Pakistan. Plasma proteins were analysed by 2D liquid chromatographic system in which samples were initially fractionated by chromatofocusing and the selected fractions were further analysed by reverse-phase high performance liquid chromatography. The proteins which showed variation between test and control samples were identified by MALDI-TOF analysis. All the samples belonging to the control and diabetic groups were then analyzed by ELISA and estimated four proteins which were found to vary. Levels of apolipoprotein A-I was found to decrease by -6.4% while apolipoprotein E, leptin and C reactive protein (CRP) were increased by +802, +842 and +872%, respectively, in the diabetic patients as compared to the controls. The discovery of these marker proteins might thus provide an adjunctive method for early detection of risk for this disease. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015604     DOI: 10.1016/j.jpba.2009.11.016

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  8 in total

1.  Proteomic technologies for the discovery of type 1 diabetes biomarkers.

Authors:  Wenbo Zhi; Sharad Purohit; Colleen Carey; Meiyao Wang; Jin-Xiong She
Journal:  J Diabetes Sci Technol       Date:  2010-07-01

Review 2.  Overview of genomics and post-genomics research on type 2 diabetes mellitus: Future perspectives and a framework for further studies.

Authors:  Battini Mohan Reddy; Rayabarapu Pranavchand; S A A Latheef
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

3.  An engineered ClyA nanopore detects folded target proteins by selective external association and pore entry.

Authors:  Misha Soskine; Annemie Biesemans; Benjamien Moeyaert; Stephen Cheley; Hagan Bayley; Giovanni Maglia
Journal:  Nano Lett       Date:  2012-08-06       Impact factor: 11.189

4.  Microarray analysis of rat pancreas reveals altered expression of Alox15 and regenerating islet-derived genes in response to iron deficiency and overload.

Authors:  Richard Coffey; Hyeyoung Nam; Mitchell D Knutson
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

Review 5.  Perspective: a systems approach to diabetes research.

Authors:  Martin Kussmann; Melissa J Morine; Jörg Hager; Bernhard Sonderegger; Jim Kaput
Journal:  Front Genet       Date:  2013-10-16       Impact factor: 4.599

6.  Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers.

Authors:  Maria A Sleddering; Albert J Markvoort; Harish K Dharuri; Skhandhan Jeyakar; Marieke Snel; Peter Juhasz; Moira Lynch; Wade Hines; Xiaohong Li; Ingrid M Jazet; Aram Adourian; Peter A J Hilbers; Johannes W A Smit; Ko Willems Van Dijk
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

7.  The application of post-translational modification oriented serum proteomics to assess experimental diabetes with complications.

Authors:  Han-Min Chen; Lin-Chien Lee; Kuang-Yu Hu; Wei-Jern Tsai; Cheng Huang; Hui-Jen Tsay; Hui-Kang Liu
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

8.  Prospection of plasma proteins as biomarkers for diabetes mellitus monitoring.

Authors:  Liliane de Paula Silva; Fabiane Gomes de Moraes Rego; Geraldo Picheth; Marcelo Müller-Santos; Dayane Alberton
Journal:  J Diabetes Metab Disord       Date:  2021-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.